ExQor is developing a unique biologic.ExQor's biologic would restore cognitive capabilities by regenerating neurons and their connections that were damaged by disease.
ExQor's biologic would treat learning and memory issues quicker and better and with less side effects than existing treatment methods.
Treatments for multiple CNS disorders are possible using ExQor's biologic.
ExQor has shown preclinical success in restoring cognitive functioning in Alzheimer's, HIV associated dementias, and also recovery from addictions like methamphetamine addiction.
ExQor is preparing its first IND application to FDA for treating cognitive impairments that are consequences of Alzheimer’s disease.
ExQor applications to FDA for treating additional neurodegenerative disorders with its biologic would follow.
MRI Detection of Very Early Stage Alzheimer's
ExQor also has diagnostic agent development programs using gadolinium and SPIONs (superparamagnetic iron oxide nanoparticles) that would enable conventional MRI systems to have similar molecular resolution to PET, which is not available in most clinics.
ExQor's molecular level MRI agent would first be used for detecting and assessing very early-stage Alzheimer's or identifying mild cognitive impairment (MCI) that could convert to Alzheimer's.
Concurrent use of ExQor's biologic at the point of early MRI detection could treat and mitigate progression of Alzheimer's.
Strong AI Background
Because ExQor's founders' also have extensive experience in developing AI systems.ExQor is developing a unique AI system for detecting and treating neurodegenerative disorders.
Some ExQor AI goals are precision dosing, improved maintenance and patient compliance, and personalized treatment with ExQor's biologic.
ExQor also could apply its AI knowhow to its molecular level MRI diagnostic agents for improved and/or preventive Alzheimer's treatments using ExQor's biologic.
ExQor has multiple allowed patents and patents pending.
© 2024 ExQor Technologies, Inc . All rights reserved
